OBJECTIVES: Beryllium sensitisation (BeS) and chronic beryllium disease (CBD) are caused by exposure to beryllium with susceptibility affected by at least one well-studied genetic host factor, a glutamic acid residue at position 69 (E69) of the HLA-DPβ chain (DPβE69). However, the nature of the relationship between exposure and carriage of the DPβE69 genotype has not been well studied. The goal of this study was to determine the relationship between DPβE69 and exposure in BeS and CBD. METHODS: Current and former workers (n=181) from a US nuclear weapons production facility, the Y-12 National Security Complex (Oak Ridge, Tennessee, USA), were enrolled in a case-control study including 35 individuals with BeS and 19 with CBD. HLA-DPB1 genotypes were determined by PCR-SSP. Beryllium exposures were assessed through worker interviews and industrial hygiene assessment of work tasks. RESULTS: After removing the confounding effect of potential beryllium exposure at another facility, multivariate models showed a sixfold (OR 6.06, 95% CI 1.96 to 18.7) increased odds for BeS and CBD combined among DPβE69 carriers and a fourfold (OR 3.98, 95% CI 1.43 to 11.0) increased odds for those exposed over an assigned lifetime-weighted average exposure of 0.1 μg/m(3). Those with both risk factors had higher increased odds (OR 24.1, 95% CI 4.77 to 122). CONCLUSION: DPβE69 carriage and high exposure to beryllium appear to contribute individually to the development of BeS and CBD. Among workers at a beryllium-using facility, the magnitude of risk associated with either elevated beryllium exposure or carriage of DPβE69 alone appears to be similar.
OBJECTIVES:Beryllium sensitisation (BeS) and chronic beryllium disease (CBD) are caused by exposure to beryllium with susceptibility affected by at least one well-studied genetic host factor, a glutamic acid residue at position 69 (E69) of the HLA-DPβ chain (DPβE69). However, the nature of the relationship between exposure and carriage of the DPβE69 genotype has not been well studied. The goal of this study was to determine the relationship between DPβE69 and exposure in BeS and CBD. METHODS: Current and former workers (n=181) from a US nuclear weapons production facility, the Y-12 National Security Complex (Oak Ridge, Tennessee, USA), were enrolled in a case-control study including 35 individuals with BeS and 19 with CBD. HLA-DPB1 genotypes were determined by PCR-SSP. Beryllium exposures were assessed through worker interviews and industrial hygiene assessment of work tasks. RESULTS: After removing the confounding effect of potential beryllium exposure at another facility, multivariate models showed a sixfold (OR 6.06, 95% CI 1.96 to 18.7) increased odds for BeS and CBD combined among DPβE69 carriers and a fourfold (OR 3.98, 95% CI 1.43 to 11.0) increased odds for those exposed over an assigned lifetime-weighted average exposure of 0.1 μg/m(3). Those with both risk factors had higher increased odds (OR 24.1, 95% CI 4.77 to 122). CONCLUSION: DPβE69 carriage and high exposure to beryllium appear to contribute individually to the development of BeS and CBD. Among workers at a beryllium-using facility, the magnitude of risk associated with either elevated beryllium exposure or carriage of DPβE69 alone appears to be similar.
Authors: Laura Welch; Knut Ringen; Eula Bingham; John Dement; Tim Takaro; William McGowan; Anna Chen; Patricia Quinn Journal: Am J Ind Med Date: 2004-09 Impact factor: 2.214
Authors: M Abbas Virji; Aleksandr B Stefaniak; Gregory A Day; Marcia L Stanton; Michael S Kent; Kathleen Kreiss; Christine R Schuler Journal: Ann Occup Hyg Date: 2010-08-30
Authors: P C Kelleher; J W Martyny; M M Mroz; L A Maier; A J Ruttenber; D A Young; L S Newman Journal: J Occup Environ Med Date: 2001-03 Impact factor: 2.162
Authors: James A Snyder; Eugene Demchuk; Erin C McCanlies; Christine R Schuler; Kathleen Kreiss; Michael E Andrew; Bonnie L Frye; James S Ensey; Marcia L Stanton; Ainsley Weston Journal: J R Soc Interface Date: 2008-07-06 Impact factor: 4.118
Authors: Lisa A Maier; Dierdre S McGrath; Hiroe Sato; Penny Lympany; Ken Welsh; Roland Du Bois; Lori Silveira; Andrew P Fontenot; Richard T Sawyer; Eric Wilcox; Lee S Newman Journal: J Immunol Date: 2003-12-15 Impact factor: 5.422
Authors: Aleksandr B Stefaniak; Mark D Hoover; Gregory A Day; Robert M Dickerson; Eric J Peterson; Michael S Kent; Christine R Schuler; Patrick N Breysse; Ronald C Scripsick Journal: J Environ Monit Date: 2004-03-22
Authors: Kathleen Kreiss; Ethan D Fechter-Leggett; Erin C McCanlies; Christine R Schuler; Ainsley Weston Journal: J Occup Environ Med Date: 2016-09 Impact factor: 2.162
Authors: Lori J Silveira; Erin C McCanlies; Tasha E Fingerlin; Michael V Van Dyke; Margaret M Mroz; Matthew Strand; Andrew P Fontenot; Natalie Bowerman; Dana M Dabelea; Christine R Schuler; Ainsley Weston; Lisa A Maier Journal: J Immunol Date: 2012-09-12 Impact factor: 5.422
Authors: James Crooks; Margaret M Mroz; Michael VanDyke; Alison McGrath; Christine Schuler; Erin C McCanlies; M Abbas Virji; Kenneth D Rosenman; Milton Rossman; Carol Rice; Dimitri Monos; Tasha E Fingerlin; Lisa A Maier Journal: Occup Environ Med Date: 2021-09-17 Impact factor: 4.402
Authors: Marharyta Petukh; Bohua Wu; Shannon Stefl; Nick Smith; David Hyde-Volpe; Li Wang; Emil Alexov Journal: PLoS One Date: 2014-11-04 Impact factor: 3.240
Authors: Lori J Silveira; Matthew Strand; Michael V Van Dyke; Margaret M Mroz; Anna V Faino; Dana M Dabelea; Lisa A Maier; Tasha E Fingerlin Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240
Authors: Raju S R Adduri; Ravikiran Vasireddy; Margaret M Mroz; Anisha Bhakta; Yang Li; Zhe Chen; Jeffrey W Miller; Karen Y Velasco-Alzate; Vanathi Gopalakrishnan; Lisa A Maier; Li Li; Nagarjun V Konduru Journal: Int Arch Occup Environ Health Date: 2022-05-12 Impact factor: 2.851